Aviva’s Relmada Therapeutics RLMD Stock Holding History

Aviva’s Portfolio RLMD Stock Details RLMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-33,559	Closed	-$1.08M	–	976
2020 Q4	$1.08M	Sell	33,559 -27,206	-45%	-$935K	0.01%	851
2020 Q3	$2.29M	Buy	+60,765	New	+$2.35M	0.01%	701

Other funds holding RLMD

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCM

Parsons Capital Management Providence, Rhode Island $2.19B AUM 20.87% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Aviva's RLMD Position: Q1 2021 in Review

Aviva sold out of Relmada Therapeutics (RLMD) in Q1 2021, closing a stake of 33,559 shares — an estimated $1.08M sold.

Aviva first reported a position in RLMD in Q3 2020 and held it in 2 quarters. The position peaked at $2.29M in Q3 2020. 82 funds tracked by Wall St. Rank hold RLMD as of Q1 2021.

Aviva reported no remaining Relmada Therapeutics position as of Q1 2021 after selling out during the quarter.
Aviva sold 33,559 Relmada Therapeutics shares in Q1 2021, an estimated $1.08M.
Aviva first reported a position in Relmada Therapeutics in Q3 2020 and held it in 2 quarters.
Aviva's Relmada Therapeutics position peaked at $2.29M in Q3 2020.
82 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q1 2021.

Based on Aviva's 13F filing for Q1 2021, filed 13 May 2021.